These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11488693)

  • 1. Meloxicam in hypersensitivity to NSAIDs.
    Nettis E; Di Paola R; Ferrannini A; Tursi A
    Allergy; 2001 Aug; 56(8):803-4. PubMed ID: 11488693
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative safety of meloxicam in NSAID-intolerant patients.
    Kosnik M; Music E; Matjaz F; Suskovic S
    Allergy; 1998 Dec; 53(12):1231-3. PubMed ID: 9930610
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
    Inomata N; Osuna H; Yamaguchi J; Onoda M; Takeshita Y; Chiba Y; Kambara T; Ikezawa Z
    J Dermatol; 2007 Mar; 34(3):172-7. PubMed ID: 17291297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema.
    Göksel O; Aydin O; Misirligil Z; Demirel YS; Bavbek S
    J Dermatol; 2010 Nov; 37(11):973-9. PubMed ID: 21039786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs.
    Senna GE; Passalacqua G; Dama A; Crivellaro M; Schiappoli M; Bonadonna P; Canonica GW
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):393-6. PubMed ID: 14768525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema.
    Colanardi MC; Nettis E; Traetta P; Daprile C; Fitto C; Aloia AM; Di Leo E; Ferrannini A; Vacca A
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):82-5. PubMed ID: 18254487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New information on clinical efficacy and tolerance of meloxicam (movalis)].
    Nasonova VA
    Ter Arkh; 1999; 71(11):45-8. PubMed ID: 10626335
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are selective COX-2 inhibitors a safe option in patients with intolerance to nonsteroidal antiinflammatory drugs?
    Quiñones Estévez MD
    J Investig Allergol Clin Immunol; 2009; 19(4):328-30. PubMed ID: 19639736
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs.
    Quaratino D; Romano A; Di Fonso M; Papa G; Perrone MR; D'Ambrosio FP; Venuti A
    Ann Allergy Asthma Immunol; 2000 Jun; 84(6):613-7. PubMed ID: 10875490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs.
    Domingo MV; Marchuet MJ; Culla MT; Joanpere RS; Guadaño EM
    J Investig Allergol Clin Immunol; 2006; 16(6):364-6. PubMed ID: 17153884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meloxicam enters competitive NSAID market.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1026. PubMed ID: 10876741
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
    Bavbek S; Dursun AB; Dursun E; Eryilmaz A; Misirligil Z
    Int Arch Allergy Immunol; 2007; 142(1):64-9. PubMed ID: 17016059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
    Prieto A; De Barrio M; Martín E; Fernández-Bohórquez M; de Castro FJ; Ruiz FJ; Herrero T; Tornero P; Rubio M
    J Allergy Clin Immunol; 2007 Apr; 119(4):960-4. PubMed ID: 17292954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam.
    Curtiss FR
    J Manag Care Pharm; 2006 Apr; 12(3):265-8. PubMed ID: 16623613
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experience with meloxicam treatment of ankylosing spondylarthritis].
    Mazurov VI; Beliaeva IB; Onushchenko IA
    Klin Med (Mosk); 2001; 79(5):53-5. PubMed ID: 11510190
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of meloxicam: a global analysis of clinical trials [British Journal of Rheumatology, 1996;35(suppl. 1):68-77].
    Fenn GC; Morant SV
    Br J Rheumatol; 1997 Jul; 36(7):817-9. PubMed ID: 9255122
    [No Abstract]   [Full Text] [Related]  

  • 18. Meloxicam in acute UV dermatitis--a pilot study.
    Bayerl C; Pagung R; Jung EG
    Photodermatol Photoimmunol Photomed; 1998; 14(5-6):167-9. PubMed ID: 9826888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The evaluation of the effectiveness and tolerance of movalis in patients with osteoarthrosis].
    Iakushin SS; Filonenko SP; Kosov IN; Sorokina OS
    Klin Med (Mosk); 1999; 77(6):47-9. PubMed ID: 10459221
    [No Abstract]   [Full Text] [Related]  

  • 20. Meloxicam-induced liver toxicity.
    Staerkel P; Horsmans Y
    Acta Gastroenterol Belg; 1999; 62(2):255-6. PubMed ID: 10427794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.